ScoreWhy is Ajanta Pharma Ltd. ?
1
High Management Efficiency with a high ROE of 21.01%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
Poor long term growth as Operating profit has grown by an annual rate 8.86% of over the last 5 years
4
Positive results in Dec 25
- NET SALES(Q) Highest at Rs 1,374.84 cr
- PBDIT(Q) Highest at Rs 382.24 cr.
- PBT LESS OI(Q) Highest at Rs 333.63 cr.
5
With ROE of 22.6, it has a Expensive valuation with a 8.3 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 3.90%, its profits have risen by 13% ; the PEG ratio of the company is 2.7
6
High Institutional Holdings at 26.56%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Consistent Returns over the last 3 years
- Along with generating 3.90% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Ajanta Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ajanta Pharma for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Ajanta Pharma
3.81%
0.14
27.26%
Sensex
-3.52%
-0.27
13.03%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.07%
EBIT Growth (5y)
8.86%
EBIT to Interest (avg)
94.49
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
1.08
Tax Ratio
21.95%
Dividend Payout Ratio
78.95%
Pledged Shares
17.29%
Institutional Holding
26.56%
ROCE (avg)
30.01%
ROE (avg)
21.01%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
32
Price to Book Value
8.35
EV to EBIT
29.65
EV to EBITDA
26.00
EV to Capital Employed
9.75
EV to Sales
6.79
PEG Ratio
2.74
Dividend Yield
0.97%
ROCE (Latest)
31.41%
ROE (Latest)
22.56%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET SALES(Q)
Highest at Rs 1,374.84 cr
PBDIT(Q)
Highest at Rs 382.24 cr.
PBT LESS OI(Q)
Highest at Rs 333.63 cr.
PAT(Q)
Highest at Rs 273.77 cr.
EPS(Q)
Highest at Rs 21.84
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Ajanta Pharma
Net Sales - Quarterly
Highest at Rs 1,374.84 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 382.24 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 333.63 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 333.63 cr has Grown at 20.47%
Year on Year (YoY)MOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 273.77 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 21.84
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
